Oxford BioDynamics (GB:OBD) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oxford BioDynamics Plc has reported continued growth in its biotechnology segment with an emphasis on the commercialization of its EpiSwitch tests, observing a revenue increase and expanding market presence through various commercial agreements. Despite an operating loss, the company has successfully secured funding to support near-term plans and has advanced its test offerings, including securing US reimbursement for its EpiSwitch PSE test and partnering with health providers for broader access.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.